Last edition
News about " Phase III Trials of ART-123 to Prevent Chemothera"
CIPN is a common and often debilitating side effect of chemotherapy agents like platinum-based drugs, taxanes, and vinca alkaloids. It causes pain, tingling, and numbness in the extremities, potentially forcing dose reductions or treatment discontinuation, which can adversely impact patient outcomes.
Phase III Trials Of ART-123 To Prevent Chemothera | 03/07/2025 | By Darshana | 149
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members